May 11, 2023
Via: World Pharma NewsToday, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. This is the first FDA-approved treatment option for this indication. “Agitation […]
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 5, 2023
September 1, 2023
August 30, 2023
September 19, 2023